[1] CHEN Fazhang-YANG Ruyi,.Research Progress of Immune Regulation of Traditional Chinese Medicine on Gastrointestinal Tumors [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2022, (01): 126-131. [doi: 10.13424/j.cnki.jsctcm.2022.01.028]
Research Progress of Immune Regulation of Traditional Chinese Medicine on Gastrointestinal Tumors
- Article number:
- 2096-1340(2022)01-0126-06
- Keywords:
- Key words： Immune function; Digestive tract tumor/accumulation; Zheng Jia; Yan; Loss of flourishing; Stone gangrene; Immunosuppression; Immune editing
- ZTFLH:
- R256.3
- Code:
- A
- Abstract:
- Abstract： Gastrointestinal tumors are common tumors in China.Western medicine mainly focuses on surgery,chemotherapy and radiotherapy.Surgery can not achieve the effect of radical cure for patients with metastasis.After longterm radiotherapy and chemotherapy,most patients have bone marrow suppression and immune decline.In the treatment of gastrointestinal tumors,traditional Chinese medicine can reduce tumor immunosuppression and inhibit the growth of tumor cells.By consulting the literature at home and abroad in recent ten years,this paper summarizes the relationship between gastrointestinal tumors and body immunity and the regulatory effect of traditional Chinese medicine on immune function.The results show that the occurrence and development of gastrointestinal tumors are closely related to body immune function,Traditional Chinese medicine can not only improve the immune function of patients,but also inhibit the proliferation of tumor cells.This article provides a reference for the treatment of gastrointestinal tumor diseases with traditional Chinese medicine.
References:
［1］邹万成，张六通，邱幸凡，等.古籍中恶性肿瘤之各种称谓文义考析［J］.湖北中医学院学报，2008，10(2):16.
［2］何伟.恶性肿瘤现代中医病因病机研究现状及问题分析［J］.中国中医基础医学志，2019，25(6):848-850.
［3］赵晓智，王浩.不同术式对结直肠癌根治术后患者应激状态与免疫功能的影响［J］.中国肿瘤临床与康复，2019，26(11):1188-1191.
［4］Wang Q，Yang L，Xu F，et al.Changes of lymphocyte subgroups in non-small cell lung cancer patients before and during chemotherapy［J］.Clin Lab，2015，61(10):1343-1351.
［5］Terrones-Campos C，Ledergerber B，Vogelius IR，et al.Lymphocyte count kinetics，factors associated with the end-of-radiation-therapy lymphocyte count，and risk of infection in patients with solid malignant tumors treated with curativeintent radiation therapy［J］.Int J Radiat Oncol Biol Phys，2019，105(4):812-823.
［6］曹雪涛.医学免疫学［M］.北京：人民卫生出版社，2018:1-2.
［7］Teng MW，Galon J，Fridman WH，et al.From mice to humans：developments in cancer immunoediting［J］.J Clin Invest，2015，125(9):3338-3346.
［8］Gabrilovich Dmitry I，Nagaraj Srinivas.Myeloid-derived suppressor cells as regulators of the immune system［J］.Nature reviews Immunology，2009，9(3):162-174.
［9］Motallebnezhad M，Jadidi-Niaragh F，Qamsari ES，et al.The immunobiology of myeloid-derived suppressor cells in cancer［J］.Tumour Biol，2016，37(2):1387-1406.
［10］何向锋，窦骏.髓源性抑制细胞在肿瘤免疫中的作用［J］.微生物学免疫学进展，2009，37(2):64-67.
［11］高晶晶，焦志军，许化溪.髓源性抑制细胞抑制机制及其抗肿瘤免疫治疗［J］.国际病理科学与临床杂志，2010，30(4):327-331.
［12］Jaufmann J，Lelis FJN，Teschner AC，et al.Human monocytic myeloidderived suppressor cells impair B-cell phenotype and function in vitro［J］.European journal of immunology，2020，50(1):33-47.
［13］Rachel F，Gabitass，Nicola E.Annels，et al.Elevated myeloid-derived suppressor cells in pancreatic，esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13［J］.Cancer Immunology，Immunotherapy，2011，60(10):1419-430.
［14］Chen MF，Kuan FC，Yen TC，et al.IL-6-stimulated CD11b+ CD14+ HLA-DR-myeloid-derived suppressor cells，are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus.Oncotarget［J］.2014，5(18):8716-8728.
［15］李晓宁.髓源性抑制细胞在胃癌肿瘤免疫中的作用［J］.临床医药文献电子杂志，2016，3(6):654.
［16］Karakasheva TA，Dominguez GA，Hashimoto A，et al.CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients［J］.JCI Insight.2018;3(6):e97022.
［17］Tanaka A，Sakaguchi S.Regulatory T cells in cancer immunotherapy［J］.Cell Research，2017，27(1)：109-118.
［18］Wang XF，Wang L.Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients［J］.International journal of clinical and experimental pathology，2015，8(5):5702-5708.
［19］Byrne William L，Mills Kingston HG，Lederer James A，et al.Targeting regulatory T cells in cancer［J］.Cancer research，2011，71(22):6915-6920.
［20］Zou L，Barnett B，Safah H，et al.Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals［J］.Cancer Res，2004，64(22)：8451-8455.
［21］Sun B，Liu M，Cui M，et al.Granzyme B-expressing treg cells are enriched in colorectal cancer and present the potential to eliminate autologous T conventional cells［J］.Immunology Letters，2020，217:7-14.
［22］Ma Q，Liu J，Wu G，et al.Pharmacol.Co-expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients［J］.Physiol，2018，45(10):1002-1009.
［23］陆威，李永翔，张尚鑫，等.胃癌患者外周血及癌组织中CD4+ CD25+调节性T细胞、转录因子Foxp3的表达及临床意义［J］.安徽医科大学学报，2013，48(7):790-793.
［24］Zhou S，Shen Z，Wang Y，et al.CCR7 Expression and Intratumoral FOXP3(+) Regulatory T Cells are Correlated with Overall Survival and Lymph Node Metastasis in Gastric Cancer［J］.PLoS ONE，2013,8(9)：e74430.
［25］Dutsch-Wicherek MM，Szubert S，Dziobek K，et al.Analysis of the treg cell population in the peripheral blood of ovarian cancer patients in relation to the long-term outcomes［J］.Ginekol Pol，2019，90(4)：179-184.
［26］毛争强.浸润性CD11b+CD15+粒细胞在人胃癌微环境中免疫抑制功能及其机制的研究［D］.武汉:华中科技大学，2013.
［27］Wang TT，Zhao YL，Peng LS，et al.Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GMCSFPDL1 pathway［J］.Gut，2017，66(11):1900-1911.
［28］郑雨佳.食管癌肿瘤微环境中TNFα诱导NK细胞表达Tim-3导致功能耗竭［D］.郑州:郑州大学，2019.
［29］李悠然，陈邑岐，王浩，等.中药汤剂联合静脉化疗方案对结直肠癌患者细胞免疫功能影响的Meta分析［J］.辽宁中医杂志，2016，43(10):2035-2041.
［30］陈舲，马耀凯，李鑫.扶正抑瘤方联合乌苯美司胶囊治疗晚期结直肠癌的临床观察［J］.癌症进展，2016，14(4):357-359.
［31］王冰.君子扶正汤对结直肠癌患者术后化疗减毒增效及增强免疫力方面的临床研究［D］.吉林:吉林大学，2014.
［32］王振东，唐建荣，李大威.清胰化积方对中晚期胰腺癌患者生存期及细胞免疫功能的影响［J］.世界中西医结合杂志，2018，13(7):984-988.
［33］黄攀，陶敏贤，许纯，等.健脾活血方联合化疗对晚期胃癌患者生活质量及免疫功能的影响［J］.湖北中医药大学学报，2016，(6):37-39.
［34］黄斯阳，罗强.黄芪多糖配合同步放化疗治疗中晚期食管癌的临床效果观察［J］.中国现代医生，2017，(35):25-28.
［35］Wang LH，Wang LL，Zhang J，et al.Th1/Th2 and Treg/Th17 cell balance in peripheral blood of patients with ovarian cancer［J］.南方医科大学学报，2017，37(8):1066-1070.
［36］许承斌，柴晓文.Th1/Th2 细胞的免疫功能变化与抗肿瘤免疫［J］.现代诊断与治疗，2009，20(3):163-165.
［37］Bern MD，Parikh BA，Yang L，et al.Inducible downregulation of MHC class I results in natural killer cell tolerance［J］.The Journal of experimental medicine，2019，216(1):99-116.
［38］Morvan MG，Lanier LL.NK cells and cancer：you can teach innate cells new tricks［J］.Nature reviews.Cancer，2015，16(1)：7-19.
［39］李豪侠.黄芪多糖对老年胰腺癌晚期患者生存质量、细胞免疫功能的影响［J］.中国中医药科技，2010，17(3):243-244.
［40］马红霞，白文梅.人参皂苷Rh_2联合化疗用于肺癌的疗效评价及对肿瘤标志物和免疫功能的影响［J］.空军医学杂志，2019，35(5):406-409.
［41］周青，孙长侠，孙斐，等.启膈化痰合剂对顺铂治疗小鼠食管癌的减毒增效作用［J］.中国现代中药，2018，20(3):283-287，297.
［42］邵扣凤，肖平.参苓白术散加减方对晚期胃癌化疗患者毒副反应及免疫功能的影响［J］.中医药导报，2016，22(8):26-28，32.
［43］郝捷.肿瘤学概论［M］.北京;人民卫生出版社，2018：62-63.
［44］路平，李荣，梁秋冬，等.中药对食管癌术后患者生活质量和免疫功能的影响［J］.新乡医学院学报，2006，(2):121-122.
［45］滕晓晶.扶正康复合剂联合顺铂抑制移植性胃癌的实验研究［D］.杭州:浙江中医药大学，2018.
［46］王国良.复方苦参注射液对晚期消化系肿瘤病人IL-2、CD4+、CD4+/CD8+及肿瘤标志物水平的影响［D］.石河子:石河子大学，2011.
［47］胡永明.参麦注射液联合吉西他滨对晚期胰腺癌患者T细胞亚群及相关细胞因子的影响研究［J］.现代实用医学，2015，27(5):628-630.
Memo
基金项目：青海省中藏局基金资助项目（2019105）